N-Methylmescaline

According to Alexander Shulgin, N-methylmescaline shows no central or peripheral effects at doses of up to 24 or 25mg, which is many times the minor or trace amounts present in peyote. Nonetheless, according to Shulgin, N-methylmescaline, in combination with potent isoquinoline monoamine oxidase inhibitors (MAOIs) that are also present in the cactus, might be the active psychedelic constituent of Pachycereus pringlei, which notably does not contain mescaline. ==Interactions==

Pharmacodynamics N-Methylmescaline shows weak affinity for serotonin receptors similarly to mescaline. It was found to have about half the serotonin receptor affinity as mescaline (A2 = 5,250nM vs. 2,240nM, respectively). In contrast to N-methylmescaline however, trichocereine (N,N-dimethylmescaline) produced similar effects to mescaline at a dose of 50mg/kg intraperitoneally, whereas it only transiently substituted for mescaline when given intracerebroventricularly. ==Chemistry==

N-Methylmescaline, also known as N-methyl-3,4,5-trimethoxyphenethylamine, is a substituted phenethylamine and scaline. ==History==

N-Methylmescaline was first described in the scientific literature by Ernst Späth and Johann Bruck in 1937. It was isolated from Lophophora williamsii (peyote) by the researchers and was also synthesized. ==Society and culture==

Legal status Canada N-Methylmescaline is not a controlled substance in Canada as of 2025. United States N-Methylmescaline is not an explicitly controlled substance in the United States. ==See also==